I think this is really important, and it's what I've focused on. The PMPRB is setting this maximum price, and it's the only location where the whole of Canada can actually have a conversation about good value for money. Once the PMPRB maximum price is set, then all of the payers, the HTAs and all of that, come into play. It's not part of this discussion, to be honest. If it helps you then not to say, “Okay, let's just talk about it: Is this is a way of establishing a price that is not excessive?”—because that's its function....
As I tried to outline, using value-based price is a nice way to operationalize that concept of “excessive”. Once you have “non-excessive” prices, then the rest of the market can work as it does currently. I hope it doesn't, because I think there are much bigger efficiencies for industry, patients and health systems by dealing with the fact that it typically takes18 months to two years from Health Canada approval to getting a reimbursed invoice. I think there are much bigger gains to be had by re-engineering that process. But Canada as a whole does need an operationally robust definition of an “excessive price”. I think that's what this is about, and if we can all focus on that, it will help us.